Solpadol 5 mg 6 Tap

Solpadol 5 mg 6 Tap

Description:

Solpadol 5 mg oro-dispersible tablets are a prescription migraine medicine containing zolmitriptan, a selective serotonin (5HT1) receptor agonist used for the acute treatment of migraine attacks with or without aura. These fast-dissolving tablets from Global Napi Pharmaceuticals are designed to melt on the tongue without the need for water, offering rapid relief from migraine headache, associated nausea, and sensitivity to light and sound. Solpadol targets intracranial blood vessels and the trigeminal pain pathway to reduce migraine intensity and duration, helping patients resume daily activities more quickly.

Indications:

• Acute treatment of migraine attacks with or without aura in adults.
• Relief of moderate to severe migraine headache pain.
• Reduction of associated migraine symptoms such as nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound).
• Use only after a clear diagnosis of migraine has been established by a healthcare professional.

Active Ingredients / Key Components:

• Zolmitriptan – 5 mg per oro-dispersible tablet.
• Excipients (oro-dispersible tablet base, sweeteners, flavoring agents, and stabilizers) – exact composition and concentrations , please check the product leaflet or the manufacturer’s official website; please refer to the official package leaflet for the full excipient list.

Dosage & Administration / How to Use:

• Use only as directed by your physician and strictly for diagnosed migraine attacks.
• Recommended adult dose: Usually 2.5 mg or 5 mg at the onset of a migraine attack, as prescribed. This specific pack contains 5 mg tablets; your doctor will determine if 5 mg is appropriate for you.
• If the migraine symptoms reappear after initial improvement, a second dose may be taken, typically at least 2 hours after the first dose, if advised by your doctor.
• Maximum daily dose: The usual maximum total dose in 24 hours is 10 mg (e.g., two 5 mg tablets), but follow your doctor’s exact instructions. Do not exceed the prescribed maximum.
• Solpadol oro-dispersible tablets are designed to dissolve on the tongue: place one tablet on the tongue and allow it to melt; swallow the dissolved contents. Water is not required but may be taken if desired.
• Can be taken with or without food; a high-fat meal may delay onset of action slightly.
• Do not use to prevent migraine attacks (not for prophylactic use); it is intended for acute treatment only when an attack has started.
• Not recommended for children and adolescents unless specifically prescribed by a specialist (age-related safety data may be limited).
• If there is no improvement in your migraine after the first dose, do not take a second dose for the same attack without medical advice.

Clinical Benefits:

• Provides targeted relief of acute migraine headache by selectively constricting dilated intracranial blood vessels.
• Helps reduce transmission in the trigeminal pain pathway, decreasing migraine-related pain signaling.
• May lessen associated symptoms such as nausea, vomiting, photophobia, and phonophobia, improving overall comfort during an attack.
• Oro-dispersible formulation allows convenient use without water, suitable for patients who experience nausea or vomiting and have difficulty swallowing tablets.

Warnings & Contraindications:

• Use only after a confirmed diagnosis of migraine by a healthcare professional; do not use for other types of headache (e.g., tension headache, cluster headache).
• Contraindicated in patients with a history of ischemic heart disease, coronary artery spasm (Prinzmetal’s angina), previous myocardial infarction, stroke or transient ischemic attack (TIA), or significant peripheral vascular disease.
• Contraindicated in uncontrolled hypertension or severe hypertension.
• Do not use if you have severe liver impairment; dose adjustment may be required in mild to moderate liver disease and must be supervised by a physician.
• Do not use concurrently with other triptans or ergotamine-containing medicines or ergot-type derivatives; allow the recommended washout period between such treatments as advised by your doctor.
• Increased risk of serotonin syndrome when used with selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), or other serotonergic drugs; monitor for symptoms such as agitation, confusion, rapid heart rate, sweating, muscle rigidity, or tremor.
• Increased zolmitriptan concentrations may occur with cimetidine, certain quinolone antibacterials, and other drugs that inhibit CYP1A2; dose adjustment or caution may be required.
• Not recommended in pregnancy or breastfeeding unless clearly needed and prescribed by a doctor after risk–benefit assessment.
• May cause drowsiness or dizziness; avoid driving or operating machinery if affected.
• Overuse of acute migraine medications, including zolmitriptan, may lead to medication-overuse headache; if headaches become more frequent, consult your doctor.
• Consult your doctor before use if pregnant, nursing, taking medications (especially antidepressants, other migraine medicines, or cimetidine), or if you have medical conditions such as heart disease, hypertension, liver disease, kidney disease, or risk factors for cardiovascular disease (e.g., smoking, diabetes, high cholesterol).
• Keep out of reach of children.

Side Effects:

• Common side effects: Dizziness, drowsiness, tingling sensation, warmth or heaviness, nausea, dry mouth, abdominal discomfort, and fatigue. These are usually mild and transient.
• Less common side effects: Palpitations, temporary increase in blood pressure, chest discomfort (non-cardiac), muscle weakness, or throat tightness.
• Serious side effects (seek immediate medical attention): Severe chest pain or tightness, shortness of breath, sudden severe abdominal pain, signs of stroke (sudden weakness, difficulty speaking, vision changes), severe allergic reaction (rash, swelling of face or throat, difficulty breathing), or symptoms suggestive of serotonin syndrome (agitation, confusion, rapid heartbeat, sweating, muscle stiffness).
• If any side effect is severe, persistent, or worrying, stop using the medicine and contact your doctor or pharmacist.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed in the original blister packaging to protect from moisture. Do not use after the expiry date stated on the pack. Keep out of reach of children.

Specifications:

• Active ingredient: zolmitriptan 5 mg per tablet.
• Form: oro-dispersible tablets (dissolve on the tongue).
• Pack size: 6 tablets per pack.
• Route of administration: oral.
• Intended use: prescription migraine medicine for acute attacks in adults, as directed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.